Superworth

Bioventus BVS

Medical - Instruments & Supplies, Healthcare
$13.15
−1.31%
Market cap
$1.1B
PE
17.1×
Forward PE
n/m
not a meaningful number
Price to sales
1.9×
EV/EBIT
23.6×
Revenue, 12 months
$585.6M
+4% on a year ago
Net margin
9.4%
Free cash flow yield
8.5%

Bioventus trades at 17.1× trailing earnings. Revenue was $585.6M over the last twelve months, up 4% on a year earlier with a 9% net margin.

Charts

Financials

Income statement for BVS, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$135.4M+8%$129.5M+9%$151.2M+10%$139M+15%$153.6M+14%$123.9M−4%$147.7M−2%$138.7M−0%$157.9M+3%$132.1M+7%$153.2M+4%$142.4M+3%
Cost of revenue$49.1M−5%$41.1M−9%$47.6M−1%$45.4M+8%$51M+4%$40.8M−1%$45.6M−4%$44.4M−2%$49.1M−4%$41.3M+1%$47.5M+4%$45.3M+2%
Gross profit$86.3M+16%$88.4M+20%$103.6M+16%$93.6M+19%$102.7M+19%$83.1M−6%$102.1M−2%$94.2M+1%$108.8M+6%$90.8M+9%$105.7M+4%$97.1M+3%
R&D$3.3M−45%$2.6M−30%$4.2M+24%$3.8M+28%$3.3M+0%$3M+15%$3.2M−25%$2.9M−24%$3M−8%$2.5M−18%$3.2M+0%$3.4M+18%
SG&A$78.4M+1%$78.8M−3%$96.7M+29%$81.5M+17%$86.9M+11%$73.5M−7%$79.1M−18%$78.7M−4%$82.8M−5%$78.3M+7%$82.7M+5%$82.9M+6%
$1.2M$4.9M−$31.5M$3.6M+51%$7.7M+561%$4.9M−1%$18.4M$11.3M+209%$19.5M+153%$8.4M+73%$19.1M+4%$9.7M−14%
Interest expense$10.3M+39%$10.3M+7%$9.9M−6%$9.5M−6%$9M−13%$7.5M−27%$7.5M−25%$6.2M−35%$5.3M−41%$4.3M−42%$4.1M−46%$3.8M−39%
Pre-tax income−$8.4M−74%−$5.5M−95%−$41.6M+855%−$5.3M−36%−$53K−99%−$3.4M−38%$10.3M$4.7M$14.1M$4.5M$15.3M+48%$6.2M+32%
−$750K−93%$907K−$7.3M$589K−2%$550K−$95K$1M$664K+13%−$3.2M$571K−$20.9M−$701K
Net income−$6.1M−81%−$4.9M−97%−$25.7M+598%−$5.2M−29%−$388K−94%−$2.6M−46%$7.5M$3.2M$14.8M$3.1M$33.4M+348%$6M+90%
−$0.10−81%−$0.08−96%−$0.40+567%−$0.08−33%−$0.01−90%−$0.04−50%$0.11$0.05$0.21$0.04$0.47+327%$0.08+60%
63.1M+2%63.4M+2%64.1M+2%65.3M+4%65.5M+4%66M+4%68.5M+7%68.8M+6%69.3M+6%70M+6%70.8M+3%72.5M+5%

Interest expense: Q1 FY20: 6 months less the 3 months printed beside them.

EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 4 periods, Q4 FY21 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BVSBioventus$1.1B17.1×27.1×1.9×+4%9.4%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
STAAStaar Surgical$1.3B356×144×3.7×+51%1.1%
CDRECadre$1.3B38.9×35.9×2.0×+20%5.3%
EYENational Vision$1.4B28.1×52.7×0.7×+8%2.5%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
LMATLemaitre Vascular$1.9B28.5×42.0×7.1×+12%25.0%
INSPInspire Medical Systems$1.9B14.5×56.6×2.2×−0%15.0%
UFPTUFP Technologies$2.2B30.6×25.6×3.5×+7%11.4%
TCMDTactile Systems Technology$518.1M21.2×62.3×1.5×+17%7.1%
Peer median$1.3B29.6×44.1×2.1×+9%6.5%

More on Bioventus

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .